Albert Rauch Quotations

Near-term it's a positive for Lilly and will make it easier for Wyeth because they won't have someone launching right in front of them.

It certainly looks like Clark is willing to make tough decisions. I think eliminating 11 percent of the company is a big, major step for them. It will be really hard to maintain the corporate culture with so many positions being eliminated.

Those are two big things to overcome and basically have double-digit growth when you experience that type of generic competition.

We're not expecting any revenue impact in the third quarter or the fourth quarter,

Therapeutic substitution - substituting one product for another in the same class - just hasn't happened yet.

Each time they win, the stock will go up and each time they lose, it will go down, ... But this verdict shows that Merck's strategy of using solid science and medical information to defend themselves can work in certain situations.

The top line hasn't knocked your socks off, but certainly they've been good at controlling expenses.

This is going to set the standards for all the other inhaled insulins that are in development,

It was doing poorly with the warning of rare liver problems and now with this other warning it's hard to say how much more weakness you'll see there.

It is still too early to know if (Merck) will be able to win cases on a consistent basis,

The best defense against generic competition is innovation, because you don't have to worry so long as you come up with an innovative product that antiquates your older product, ... You can replace your own products before generic competition comes out.

If you acquire a company, you acquire all the expenses of the company. But if you sign a license, you can use cash on your balance sheet instead of your income statement.

If you had a generic Lipitor, it would be harder for Vytorin to compete. When you have a generic out there, you start worrying about therapeutic substitution.

If you've misjudged what's happened in 2005, how can you give guidance for 2006 and 2007?

If you've misjudged what's happened in '05, how can you give guidance for '06 and '07 with any confidence.

This is most concerning as it's the third late-stage failure they've had in the past year.